ERBB2 and cancer: The pathologies with the highest proportion of breast cancer deaths were lobular [23.3%, 10-year survival = 85.9% (95% CI 66.7–94.5)] triple negative [14.3%; 10-year-survival = 83.5% (95% CI 72.7–90.3)] and high-grade ER+ HER2− cancers [13.0%; 10-year-survival = 88.5% (95% CI 74.3–95.1)] although numbers in each group were relatively small limiting statistical comparison.